No link between Merck's Gardasil and MS risk, study shows

Merck's Gardasil HPV vaccine--FierceBiotech file photo
Merck's Gardasil

Merck ($MRK) and partner Sanofi ($SNY) can breathe easy: According to a new study, their blockbuster HPV shot Gardasil isn't linked to an increased risk of multiple sclerosis. In a study published Tuesday in JAMA, researchers found that in a population of 3.9 million girls and women, those vaccinated with Gardasil had lower rates of MS and similar CNS diseases. Story

Suggested Articles

Ebola has claimed thousands of lives in recent outbreaks, but now the world has a licensed vaccine option in Merck's Ervebo.

Cosette Pharmaceuticals which was formed in December with a deal for dermatology projects has gone back to G&W Labs for a liquids plant.

Takeda has spent considerable resources on its phase 3 dengue vaccine, and now data show the shot was 80% effective in preventing dengue.